Stressor states and the cation crossroads

Journal of the American College of Nutrition

Volumn 29, Issue 6, 2010, Pages 563-574

  Weber, Karl T ^a   Bhattacharya, Syamal K ^a   Newman, Kevin P ^a   Soberman, Judith E ^a   Ramanathan, Kodangudi B ^a,c   McGee, Jesse E ^a,c   Malik, Kafait U ^b   Hickerson, William L ^b  

^a Division of Cardiovascular Diseases   (United States)

^b Department of Pharmacology ^*  (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute stressor states; Calcium; Congestive heart failure; Magnesium; Neurohormonal activation; Potassium; Selenium; Zinc

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALCIUM ION; CATECHOLAMINE; CATION; MAGNESIUM ION; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PARATHYROID HORMONE; SELENIUM; TROPONIN; ZINC ION; ADENOSINE TRIPHOSPHATASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; ZINC;

AUTONOMIC NERVOUS SYSTEM; CALCIUM ABSORPTION; CALCIUM HOMEOSTASIS; CATION CROSSROAD; CATION TRANSPORT; CONGESTIVE HEART FAILURE; CRITICAL ILLNESS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROLYTE BALANCE; HEART MUSCLE NECROSIS; HOMEOSTASIS; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INJURY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPSIS; STRESS; SURVIVAL; ZINC DEFICIENCY; BLOOD; DRUG EFFECT; HEART MUSCLE; HEART MUSCLE CELL; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAGNESIUM DEFICIENCY; METABOLISM; MITOCHONDRION; NECROSIS; PHYSIOLOGICAL STRESS; PHYSIOLOGY; UPREGULATION;

ADENOSINE TRIPHOSPHATASES; ANTIOXIDANTS; CATECHOLAMINES; CATIONS; HOMEOSTASIS; HUMANS; HYPOCALCEMIA; HYPOKALEMIA; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MAGNESIUM DEFICIENCY; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; NECROSIS; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS; PARATHYROID HORMONE; PITUITARY-ADRENAL SYSTEM; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SELENIUM; STRESS, PHYSIOLOGICAL; UP-REGULATION; ZINC;

EID: 80054086559     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2010.10719895     Document Type: Article

References (137)

1. Carlstedt F, Lind L, Joachimsson PO, Rastad J, Wide L, Ljunghall S: Circulating ionized calcium and parathyroid hormone levels following coronary artery by-pass surgery. Scand J Clin Lab Invest 59:47–53, 1999.
2. Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S: Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest 28:898–903, 1998.
3. Carlstedt F, Lind L, Wide L, Lindahl B, Hänni A, Rastad J, Ljunghall S: Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest 27:977–981, 1997.
4. Hästbacka J, Pettilä V: Prevalence and predictive value of ionized hypocalcemia among critically ill patients. Acta Anaesthesiol Scand 47:1264–1269, 2003.
5. Choi YC, Hwang SY: The value of initial ionized calcium as a predictor of mortality and triage tool in adult trauma patients. J Korean Med Sci 23:700–705, 2008.
6. Cherry RA, Bradburn E, Carney DE, Shaffer ML, Gabbay RA, Cooney RN: Do early ionized calcium levels really matter in trauma patients? J Trauma 61:774–779, 2006.
7. Dickerson RN, Henry NY, Miller PL, Minard G, Brown RO: Low serum total calcium concentration as a marker of low serum ionized calcium concentration in critically ill patients receiving specialized nutrition support. Nutr Clin Pract 22:323–328, 2007.
8. Burchard KW, Simms HH, Robinson A, DiAmico R, Gann DS: Hypocalcemia during sepsis: relationship to resuscitation and hemodynamics. Arch Surg 127:265–272, 1992.
9. Cvijanovich NZ, King JC, Flori HR, Gildengorin G, Wong HR: Zinc homeostasis in pediatric critical illness. Pediatr Crit Care Med 10:29–34, 2009.
10. Cander B, DundarZD, Gul M, Girisgin S: Prognostic value of serum zinc levels in critically ill patients. J Crit Care 26:43–46, 2010.
11. Hansen O, Johansson BW, Nilsson-Ehle P: Metabolic, electrocardiographic, and hemodynamic responses to increased circulating adrenaline: effects of selective and nonselective beta adrenoceptor blockade. Angiology 41:175–188, 1990.
12. Brown MJ, Brown DC, Murphy MB: Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 309:1414–1419, 1983.
13. Reid JL, Whyte KF, Struthers AD: Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 57:23F–27F, 1986.
14. Tarditi DJ, Hollenberg SM: Cardiac arrhythmias in the intensive care unit. Semin Respir Crit Care Med 27:221–229, 2006.
15. Struthers AD, Whitesmith R, Reid JL: Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia. Lancet 1:1358–1361, 1983.
16. Lipworth BJ, McDevitt DG, Struthers AD: Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy: protection by conventional doses of spironolactone but not triamterene. Chest 98:811–815, 1990.
17. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG: Current concepts in the mechanisms and management of druginduced QT prolongation and torsade de pointes. Am Heart J 153:891–899, 2007.
18. Buckley MS, Leblanc JM, Cawley MJ: Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med 38:S253–S264, 2010.
19. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114:135–141, 2003.
20. Seelig M: Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations—magnesium and chloride loss in refractory potassium repletion. Am J Cardiol 63:4G–21G, 1989.
21. Kramer JH, Spurney C, Iantorno M, Tziros C, Mak IT, Tejero-Taldo MI, Chmielinska JJ, Komarov A, Weglicki WB: Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia. Am J Med Sci 338:22–27, 2009.
22. Rayssiguier Y: Hypomagnesemia resulting from adrenaline infusion in ewes: its relation to lipolysis. Horm Metab Res 9:309–314, 1977.
23. Escuela MP, Guerra M, A˜non JM, Martínez-Vizcaino V, Zapatero MD, Garcia-Jalón A, Celaya S: Total and ionized serum magnesium in critically ill patients. Intensive Care Med 31:151–156, 2005.
24. Ryzen E: Magnesium homeostasis in critically ill patients. Magnesium 8:201–212, 1989.
25. Ueshima K, Tachibana H, Suzuki T, Hiramori K: Factors affecting the blood concentration of ionized magnesium in patients in the acute phase of myocardial infarction. Heart Vessels 19:267–270, 2004.
26. Ceremuzynski L, Van Hao N: Ventricular arrhythmias late after myocardial infarction are related to hypomagnesemia and magnesium loss: preliminary trial of corrective therapy. Clin Cardiol 16:493–496, 1993.
27. Saleem AF, Haque A: On admission hypomagnesemia in critically ill children: risk factors and outcome. Indian J Pediatr 76:1227–1230, 2009.
28. Safavi M, Honarmand A: Admission hypomagnesemia—impact on mortality or morbidity in critically ill patients. Middle East J Anesthesiol 19:645–660, 2007.
29. Sheehan JP, Seelig MS: Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium 3:301–314, 1984.
30. Leier CV, Dei Cas L, Metra M: Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 128:564–574, 1994.
31. Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS: Hypomagnesemia and concurrent acidbase and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail 4:167–173, 2002.
32. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA: Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 62:1663–1682, 2005.
33. Joborn H, Hjemdahl P, Larsson PT, Lithell H, Lundin L, Wide L, Ljunghall S: Platelet and plasma catecholamines in relation to plasma minerals and parathyroid hormone following acute myocardial infarction. Chest 97:1098–1105, 1990.
34. Karlsberg RP, Cryer PE, Roberts R: Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 102:24–29, 1981.
35. Gunnewiek JM, Van Der Hoeven JG: Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care 10:342–346, 2004.
36. Jeremias A, Gibson CM: Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 142:786–791, 2005.
37. Maeder M, Fehr T, Rickli H, Ammann P: Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 129:1349–1366, 2006.
38. Vasile VC, Babuin L, Rio Perez JA, Alegria JR, Song LM, Chai HS, Afessa B, Jaffe AS: Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. Crit Care Med 37:140–147, 2009.
39. Tan IK, Chua KS, Toh AK: Serum magnesium, copper, and zinc concentrations in acute myocardial infarction. J Clin Lab Anal 6:324–328, 1992.
40. Versieck J, Barbier F, Speecke A, Hoste J: Influence of myocardial infarction on serum manganese, copper, and zinc concentrations. Clin Chem 21:578–581, 1975.
41. Jain VK, Mohan G: Serum zinc and copper in myocardial infarction with particular reference to prognosis. Biol Trace Elem Res 31:317–322, 1991.
42. Arnaud J, Faure H, Bourlard P, Denis B, Favier AE: Longitudinal changes in serum zinc concentration and distribution after acute myocardial infarction. Clin Chim Acta 230:147–156, 1994.
43. Lekakis J, Kalofoutis A: Zinc concentrations in serum as related to myocardial infarction. Clin Chem 26:1660–1661, 1980.
44. Berger MM, Cavadini C, Chiolero R, Dirren H: Copper, selenium, and zinc status and balances after major trauma. J Trauma 40:103–109, 1996.
45. Berger MM, Shenkin A: Update on clinical micronutrient supplementation studies in the critically ill. Curr Opin Clin Nutr Metab Care 9:711–716, 2006.
46. Berger MM, Shenkin A, Revelly JP, Roberts E, Cayeux MC, Baines M, Chioléro RL: Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients. Am J Clin Nutr 80:410–416, 2004.
47. Lindeman RD, Bottomley RG, Cornelison RL Jr, Jacobs LA: Influence of acute tissue injury on zinc metabolism in man. J Lab Clin Med 79:452–460, 1972.
48. Low WI, Ikram H: Plasma zinc in acute myocardial infarction: diagnostic and prognostic implications. Br Heart J 38:1339–1342, 1976.
49. Selmanpakoglu AN, Cetin C, Sayal A, Isimer A: Trace element (Al, Se, Zn, Cu) levels in serum, urine and tissues of burn patients. Burns 20:99–103, 1994.
50. Agay D, Anderson RA, Sandre C, Bryden NA, Alonso A, Roussel AM, Chancerelle Y: Alterations of antioxidant trace elements (Zn, Se, Cu) and related metallo-enzymes in plasma and tissues following burn injury in rats. Burns 31:366–371, 2005.
51. Berger MM: Antioxidant micronutrients in major trauma and burns: evidence and practice. Nutr Clin Pract 21:438–449, 2006.
52. Berger MM, Baines M, Raffoul W, Benathan M, Chiolero RL, Reeves C, Revelly JP, Cayeux MC, Senechaud I, Shenkin A: Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. Am J Clin Nutr 85:1293–1300, 2007.
53. Arroyo M, LaGuardia SP, Bhattacharya SK, Nelson MD, Johnson PL, Carbone LD, Newman KP, Weber KT: Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res 148:301–308, 2006.
54. Tubek S: Zinc content in lymphocytes and the activity of zinc ion efflux from lymphocytes in primary arterial hypertension. Biol Trace Elem Res 107:89–99, 2005.
55. Oster O, Drexler M, Schenk J, Meinertz T, Kasper W, Schuster CJ, Prellwitz W: The serum selenium concentration of patients with acute myocardial infarction. Ann Clin Res 18:36–42, 1986.
56. Bor MV, Cevík C, Uslu I, Güneral F, Düzgün E: Selenium levels and glutathione peroxidase activities in patients with acute myocardial infarction. Acta Cardiol 54:271–276, 1999.
57. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJS: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534, 1997.
58. Dutka DP, Olivotto I, Ward S, Nihoyannopoulos P, al-Subaili M, Oakley CM, Impallomeni M, Cleland JG: Plasma neuroendocrine activity in very elderly subjects and patients with and without heart failure. Eur Heart J 16:1223–1230, 1995.
59. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA: Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106:92–99, 2002.
60. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, Zucchelli GC, Clerico A: Cardiac natriuretic hormones, neurohormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42:627–636, 2004.
61. Buchhorn R, Hammersen A, Bartmus D, Bürsch J: The pathogenesis of heart failure in infants with congenital heart disease. Cardiol Young 11:498–504, 2001.
62. Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT: Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 46:142–146, 2005.
63. Soliman HM, Mercan D, Lobo SS, Melot C, Vincent JL: Development of ionized hypomagnesemia is associated with higher mortality rates. Crit Care Med 31:1082–1087, 2003.
64. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B: A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 28:1334–1343, 2007.
65. Adamopoulos C, Pitt B, Sui X, Love TE, Zannad F, Ahmed A: Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol 136:270–277, 2009.
66. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A: Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 3:253–260, 2010.
67. Domanski M, Tian X, Haigney M, Pitt B: Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 12:327–332, 2006.
68. Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC: Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439, 2006.
69. Weber KT: Furosemide in the long-term management of heart failure: the good, the bad and the uncertain. J Am Coll Cardiol 44:1308–1310, 2004.
70. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100:1311–1315, 1999.
71. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E: Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42:705–708, 2003.
72. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes W: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717, 1999.
73. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ: Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 103:197–207, 1997.
74. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT: Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 331:30–34, 2006.
75. LaGuardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT: Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 332:112–118, 2006.
76. Alsafwah S, LaGuardia SP, Nelson MD, Battin DL, Newman KP, Carbone LD, Weber KT: Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci 335:292–297, 2008.
77. Ulrich S, Hersberger M, Fischler M, Huber LC, Senn O, Treder U, Speich R, Schmid C: Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension. Open Respir Med J 3:53–60, 2009.
78. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, Borba VZ: Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int 20:1881–1887, 2009.
79. Fertig A, Webley M, Lynn JA: Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J 56:45–47, 1980.
80. Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M: Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA 244:1351–1353, 1980.
81. Resnick LM, Laragh JH: Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 78:385–390, 1985.
82. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C: Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 8:884–893, 1995.
83. Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, Ayav A, Weryha G, Mirallie E, Bresler L: Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146:1035–1041, 2009.
84. Andersson P, Rydberg E, Willenheimer R: Primary hyperparathyroidism and heart disease—a review. Eur Heart J 25:1776–1787, 2004.
85. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT: Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111:871–878, 2005.
86. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT: Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 290:H286–H294, 2006.
87. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT: Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci 335:105–110, 2008.
88. Gandhi MS, Deshmukh PA, Kamalov G, Zhao T, Zhao W, Whaley JT, Tichy JR, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT: Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol 52:245–252, 2008.
89. Kamalov G, Deshmukh PA, Baburyan NY, Gandhi MS, Johnson PL, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT: Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol 53:414–423, 2009.
90. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, Mancini DM, DiSesa VJ, Attie MF: Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 96:35–41, 1994.
91. Schmid C, Kiowski W: Hyperparathyroidism in congestive heart failure. Am J Med 104:508–509, 1998.
92. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, Kinugawa T, Osaki S, Kato M, Tomikura Y, Igawa O, Hisatome I, Bilezikian JP, Shigemasa C: Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab 87:4722–4727, 2002.
93. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 41:105–112, 2003.
94. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, Matsuoka K, Nakamura T, Koji T, Ito M: Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart 95:395–398, 2009.
95. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W: Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 31:1591–1598, 2010.
96. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J: Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119:2765–2771, 2009.
97. Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Ärnlöv J: Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 12:1186–1192, 2010.
98. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J: Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 76:470–473, 1985.
99. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P: Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol 57:51–55, 2002.
100. Jarvis JK, Miller GD: Overcoming the barrier of lactose intolerance to reduce health disparities. J Natl Med Assoc 94:55–66, 2002.
101. Cohen AJ, Roe FJ: Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol 38:237–253, 2000.
102. Teucher B, Dainty JR, Spinks CA, Majsak-Newman G, Berry DJ, Hoogewerff JA, Foxall RJ, Jakobsen J, Cashman KD, Flynn A, Fairweather-Tait SJ: Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res 23:1477–1485, 2008.
103. Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Bieglmayer C, Pacher R, Maurer G, Fialka-Moser V, Pietschmann P: Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant 22:843–850, 2003.
104. Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K, Satoh R, Katagiri T: Congestive heart failure is associated with the rate of bone loss. J Intern Med 253:439–446, 2003.
105. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG: Femoral bone mineral density in patients with heart failure. Osteoporos Int 17:1420–1427, 2006.
106. Frost RJ, Sonne C, Wehr U, Stempfle HU: Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 156:309–314, 2007.
107. Abou-Raya S, Abou-Raya A: Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr 49:250–254, 2009.
108. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA: Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 118:1946–1952, 2008.
109. Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, Khan BQ, Gupta M, Ahmad K, Khouzam RN, Dishmon DA, Nesheiwat JP, Hajjar MA, Chishti WA, Nasser W, Khan M, Womack CR, Cho T, Haskin AR, Weber KT: Fracture risk in men with congestive heart failure: risk reduction with spironolactone. J Am Coll Cardiol 52:135–138, 2008.
110. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, Ando T, Kurokawa H, Kondo T, Nagamura Y, Ezaki K, Hishida H: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89:691–695, 2002.
111. Kuwabara Y, Sato Y, Miyamoto T, Taniguchi R, Matsuoka T, Isoda K, Yamane K, Nishi K, Fujiwara H, Takatsu Y: Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J 71:1047–1051, 2007.
112. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH: Cardiac troponin and outcome in acute heart failure. N Engl J Med 358:2117–2126, 2008.
113. Zairis MN, Tsiaousis GZ, Georgilas AT, Makrygiannis SS, Adamopoulou EN, Handanis SM, Batika PC, Prekates AA, Velissaris D, Kouris NT, Mytas DZ, Babalis DK, Karidis KS, Foussas SG: Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 141:284–290, 2009.
114. Löwbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J: Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest 64:667–676, 2004.
115. Horwich TB, Patel J, MacLellan WR, Fonarow GC: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108:833–838, 2003.
116. Sukova J, Ostadal P, Widimsky P: Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol 12:153–156, 2007.
117. Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Mustonen H, Porela P, Harjola VP: Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 10:772–779, 2008.
118. Sato Y, Nishi K, Taniguchi R, Miyamoto T, Fukuhara R, Yamane K, Saijyo S, Tanada Y, Yamamoto E, Goto T, Takahashi N, Fujiwara H, Takatsu Y: In patients with heart failure and nonischemic heart disease, cardiac troponin T is a reliable predictor of long-term echocardiographic changes and adverse cardiac events. J Cardiol 54:221–230, 2009.
119. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS: Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 54:1715–1721, 2009.
120. Garcia Zozaya JL, Padilla Viloria M: [Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-aldosterone system] [Spanish]. Invest Clin 38(Suppl 2):27–40, 1997.
121. Golik A, Modai D, Averbukh Z, Sheffy M, Shamis A, Cohen N, Shaked U, Dolev E: Zinc metabolism in patients treated with captopril versus enalapril. Metabolism 39:665–667, 1990.
122. Golik A, Zaidenstein R, Dishi V, Blatt A, Cohen N, Cotter G, Berman S, Weissgarten J: Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr 17:75–78, 1998.
123. Chmielnicka J, Zareba G, Witasik M, Brzeźnicka E: Zincselenium interaction in the rat. Biol Trace Elem Res 15:267–276, 1988.
124. Kamalov G, Ahokas RA, Zhao W, Zhao T, Shahbaz AU, Johnson PL, Bhattacharya SK, Sun Y, Gerling IC, Weber KT: Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism. J Cardiovasc Pharmacol 55:248–254, 2010.
125. Prabhu KS, Zamamiri-Davis F, Stewart JB, Thompson JT, Sordillo LM, Reddy CC: Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW 264.7 macrophages: role of nuclear factor-jB in up-regulation. Biochem J 366(Pt 1):203–209, 2002.
126. Hatanaka N, Nakaden H, Yamamoto Y, Matsuo S, Fujikawa T, Matsusue S: Selenium kinetics and changes in glutathione peroxidase activities in patients receiving long-term parenteral nutrition and effects of supplementation with selenite. Nutrition 16:22–26, 2000.
127. Weiss SL, Evenson JK, Thompson KM, Sunde RA: The selenium requirement for glutathione peroxidase mRNA level is half of the selenium requirement for glutathione peroxidase activity in female rats. J Nutr 126:2260–2267, 1996.
128. Xia YM, Hill KE, Burk RF: Biochemical studies of a seleniumdeficient population in China: measurement of selenium, glutathione peroxidase and other oxidant defense indices in blood. J Nutr 119:1318–1326, 1989.
129. van Rij AM, Thomson CD, McKenzie JM, Robinson MF: Selenium deficiency in total parenteral nutrition. Am J Clin Nutr 32:2076–2085, 1979.
130. Reeves WC, Marcuard SP, Willis SE, Movahed A: Reversible cardiomyopathy due to selenium deficiency. JPEN J Parenter Enteral Nutr 13:663–665, 1989.
131. Boldery R, Fielding G, Rafter T, Pascoe AL, Scalia GM: Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy. Heart Lung Circ 16:123–126, 2007.
132. Song Y, Wang J, Li XK, Cai L: Zinc and the diabetic heart. Biometals 18:325–332, 2005.
133. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L: Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113:544–554, 2006.
134. Demling RH, DeBiasse MA: Micronutrients in critical illness. Crit Care Clin 11:651–673, 1995.
135. Witte KK, Clark AL, Cleland JG: Chronic heart failure and micronutrients. J Am Coll Cardiol 37:1765–1774, 2001.
136. Sriram K, Lonchyna VA: Micronutrient supplementation in adult nutrition therapy: practical considerations. JPEN J Parenter Enteral Nutr 33:548–562, 2009.
137. Bhattacharya SK, Ahokas RA, Carbone LD, Newman KP, Gerling IC, Sun Y, Weber KT: Macro-and micronutrients in African-Americans with heart failure. Heart Fail Rev 11:45–55, 2006.